AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
21.50
-1.06 (-4.70%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close22.56
Open22.52
Bid21.50 x 1800
Ask21.54 x 800
Day's range21.24 - 22.59
52-week range17.15 - 50.10
Volume1,438,142
Avg. volume1,035,324
Market cap995.912M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
Press releases
  • Business Wire

    Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

    Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that its sterile fill production facility in Athlone, Ireland has received approval from U.S. Food and Drug Administration (FDA) to produce Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the U.S. market. The regulatory clearance of the plant follows a successful preapproval inspection of the facility and FDA review of the New Drug Application Prior Approval Supplement (PAS), which added the Athlone production facility as a drug product manufacturer for Rocklatan®.

  • Business Wire

    Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe

    Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that the European Medicines Agency (EMA) has accepted for review the marketing authorisation application (MAA) for Roclanda ® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Roclanda® is currently marketed as Rocklatan® in the United States, where it is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. An opinion from the EMA’s Committee for Medicinal Products for Human Use on the MAA for Roclanda® is expected in late 2020.

  • Business Wire

    Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance

    Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Amine Sinmazisik as Director, Finance, reporting to Christopher Staten, Aerie’s Vice President of Finance. Ms. Sinmazisik will oversee the accounting and finance duties associated with revenue accounting and financial planning and analysis for the Company. She most recently held related positions at AdvanSix, Inc. and Eagle Pharmaceuticals, Inc.

  • Business Wire

    Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that it has submitted the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the European Medicines Agency (EMA). Should the MAA for Roclanda® be accepted for review by the EMA, an opinion from the Committee for Medicinal Products for Human Use is expected in approximately 12 months.

  • Business Wire

    Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present in a fireside discussion at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 8:00 a.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

  • Business Wire

    Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the European Commission (EC) has granted a marketing authorisation for Rhokiinsa® (netarsudil ophthalmic solution) 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.

  • Business Wire

    Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program

    Company Plans to Commence Phase 2b Study in Dry Eye Subjects in Late 2020

  • Business Wire

    Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:35 p.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

  • Business Wire

    Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today reported positive topline results for the Company’s Phase 2 clinical trial evaluating netarsudil ophthalmic solution in Japanese patients. Netarsudil is a Rho kinase (ROCK) inhibitor specifically designed to increase outflow of aqueous humor through the trabecular meshwork, the eye’s primary drainage pathway. Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa® in the United States and is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Business Wire

    Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its third quarter 2019 financial results will be released after the market closes on Wednesday, November 6, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com.

  • Business Wire

    Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., Ph.D., Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on November 11, 2019 and will direct the Company’s preclinical and clinical research and development groups, as well as medical and professional affairs.

  • Business Wire

    Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that patient enrollment in its Phase 2 clinical trial of AR-1105 in patients with macular edema due to retinal vein occlusion (RVO) is complete several weeks ahead of schedule. AR-1105 is an investigational sustained-release, bio-erodible intravitreal implant containing dexamethasone. The Phase 2 study (AR-1105-CS201), conducted at 19 centers in the United States, had an enrollment target of 45 patients.

  • Business Wire

    Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer, reporting to John LaRocca, Aerie’s General Counsel. Ms. Davis will oversee the world wide compliance and data privacy functions for the Company.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more